Novartis reported strong results for the fourth quarter of 2025, with a net sales growth of 1% and an operational core income increase of 24%. Key brands like Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx continued to perform well. The company also achieved several milestones in innovation and filed multiple regulatory applications for new therapies. The outlook for 2026 includes low single-digit growth in net sales and operational core income.

In the business year 2025, Novartis saw an 8% growth in net sales and a 21% increase in operational income. The core net income rose by 11% and key brands maintained strong growth. The company also focused on capital structure and debt management, with notable investments in research and development. The proposed dividend for 2025 is CHF 3.70 per share, a 5.7% increase from the previous year.

Novartis continues to prioritize innovation in pharmaceuticals, focusing on key therapeutic areas and investing in new technologies. The company aims to accelerate growth, achieve strong financial performance, and enhance its workforce capabilities. Novartis has a strategic focus on markets like the USA, China, Germany, and Japan for growth opportunities.

In the fourth quarter of 2025, Novartis experienced challenges due to generic competition and adjustments in the US market. However, key brands like Kisqali, Kesimpta, Pluvicto, and Cosentyx showed positive growth trends. The company also made progress in regulatory approvals and clinical trial results for various treatments in the pipeline.

Novartis announced a proposed dividend of CHF 3.70 per share for 2025, reflecting the company’s financial performance and commitment to shareholders. The company also outlined its outlook for 2026, expecting growth in net sales and operational core income. Novartis aims to maintain a balanced approach to investments, capital structure, and shareholder returns.

Read more at GlobeNewswire: Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im